Grosera (Rosuvastatin)

Grosera is indicated for patients who need to lower elevated cholesterol and reduce the risk of cardiovascular events.

• Treatment of primary hypercholesterolemia, including heterozygous familial hypercholesterolemia.
• Adjunct therapy for mixed dyslipidemia when diet and lifestyle changes are insufficient.
• Primary prevention of myocardial infarction, stroke, and other atherosclerotic cardiovascular disease in adults with risk factors.
• Secondary prevention of cardiovascular events in patients with established coronary artery disease.
• Use in combination with other lipid‑lowering agents such as ezetimibe when monotherapy does not achieve target LDL levels.

Like other members of the statin class, Grosera can be associated with a range of side effects that differ in how often they occur and how severe they may be for individual patients.

Common

• Headache, usually mild, transient, and may improve without specific treatment.
• Myalgia or muscle tenderness, often described as a dull ache without accompanying weakness.
• Gastrointestinal upset, including abdominal discomfort, nausea, or occasional diarrhea.
• Fatigue or a general feeling of being unusually tired, which may lessen over time.
• Elevated blood glucose levels in some patients, particularly those with pre‑existing diabetes risk.

Serious

• Significant increase in liver transaminases (ALT, AST), indicating possible hepatic injury that requires monitoring.
• Rare cases of rhabdomyolysis, characterized by severe muscle pain, marked weakness, and dark‑colored urine, which can lead to kidney complications.

Before starting Grosera, healthcare providers assess several safety considerations to minimize risks and ensure appropriate use.

• Assess baseline liver function tests because statins can affect hepatic enzymes.
• Evaluate renal function, especially in patients with chronic kidney disease, as dose adjustment may be needed.
• Review patient’s medication history for potential drug interactions that could increase statin exposure.
• Consider the risk of myopathy in patients with hypothyroidism or a history of muscle disorders.
• Counsel women of childbearing potential about the lack of established safety data during pregnancy.
• Monitor fasting lipid profile periodically to gauge therapeutic response.
• Advise patients to report unexplained muscle pain, weakness, or dark urine promptly.

Grosera may interact with other medicines, affecting its efficacy or increasing the risk of adverse effects.

Avoid

• Concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors) can markedly raise rosuvastatin levels.
• Co‑administration with fibrates such as gemfibrozil increases the risk of myopathy and should be avoided.

Use with caution

• Concurrent use with other lipid‑lowering agents (e.g., ezetimibe, niacin) may require dose adjustment and close monitoring.
• Anticoagulants like warfarin may have altered INR values; periodic coagulation monitoring is advised.
• Certain antacids containing aluminum or magnesium can reduce rosuvastatin absorption; spacing doses may mitigate the effect.
• Immunosuppressants such as cyclosporine can increase rosuvastatin exposure and may need dose reduction.